Evidence map›Paper›PMID 36790479›Full record

ArticleVirchows Archiv : an international journal of pathology2023

Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer.

Sean M Hacking, Yihong Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Sean M HackingLaboratory Medicine Program, Toronto General Hospital, Temerty Faculty of Medicine at the University of Toronto, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. Sean.Hacking@uhn.ca.ORCID http://orcid.org/0000-0001-6061-0781
Yihong WangDepartment of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA.
Brown University · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Do traditional prognostic factors fully account for the diversity of clinical behavior in breast cancer? Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer seen to have a poor prognosis, although there is great variation in clinical outcomes. Most recently, novel approaches have targeted the tumoral microenvironment (TME) to determine prognosis and tumor-associated stroma has become increasingly recognized as a potential biomarker to predict treatment response and prognosis in TNBC. The principle aim of this paper is to demonstrate an approach to stromal grading in TNBC, with consideration of its utility for predicting pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and clinical survival outcomes. We evaluated 152 TNBC cases from the Firehose Legacy TCGA Cohort and validated our findings in a series of 110 patients from our health system. Stromal grading correlated with clinical outcomes related to prognosis and response to NAC, advanced pathologic stage, as well as clinical demographics like age over 50 years with good interobserver reliability (83.6-89.1%). Looking forward, the TME could carve out a more precision-based care in TNBC and breast cancer generally.

Indexed as

Triple Negative Breast NeoplasmsBiomarkers, TumorHumansMiddle AgedNeoadjuvant TherapyReproducibility of ResultsTumor MicroenvironmentBiomarkers, TumorpCRPrognosisStromal gradeTriple-negative breast cancerTumor-associated stroma; Tumor microenvironment

Identifiers

PMID36790479
OpenAlexW4320856252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.